Aspira Women's Health (AWHL) AI Stock Analysis

• Market Cap: $14.80M
• Dividend Yield: N/A
• Average Volume (3M): 103.33K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: 4.10%
• EPS Growth: 67.32%
• Country: US
• Employees: 66
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Diagnostics & Research
• EPS (TTM): -0.07
• Shares Outstanding: 35,655,920
• 10 Day Avg. Volume: 90,618
• 30 Day Avg. Volume: 103,330
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.44
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 48 Neutral
• Price Target: $0.00 ▼(-100.00% Downside)

The company's challenging financial position, marked by unprofitability and negative equity, significantly impacts its stock score. While technical indicators show some positive momentum, the lack of profitability and adverse corporate events weigh heavily on the overall assessment.

Aspira Women's Health Business Overview & Revenue Model

Company Description

Aspira Women's Health (AWHL) is a healthcare company focused on improving women's health through innovative diagnostic solutions. The company specializes in developing and commercializing advanced tests that aid in the early detection of ovarian cancer and other gynecologic conditions. AWHL's core products include the Ova1 and Overa tests, which utilize a proprietary algorithm to assess the risk of malignancy in adnexal masses, providing valuable information for healthcare providers and patients. By combining scientific expertise with a commitment to women's health, Aspira aims to enhance patient outcomes and empower women in their healthcare journeys.

How the Company Makes Money

Aspira Women's Health generates revenue primarily through the sale of its diagnostic tests to healthcare providers, hospitals, and laboratories. The company offers its Ova1 and Overa tests, which are reimbursable under various insurance plans, enabling providers to bill for the tests and receive compensation. Additionally, AWHL may engage in partnerships with other healthcare organizations and pharmaceutical companies to expand its market reach and enhance product offerings. Revenue is also supported by ongoing research and development initiatives aimed at introducing new products and improving existing tests, which can attract further investment and funding opportunities.

Aspira Women's Health Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

Aspira Women's Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.43
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AWHL, the sentiment is Positive. The current price of 0.43 is below the 20-day moving average (MA) of 0.44, above the 50-day MA of 0.31, and above the 200-day MA of 0.29, indicating a neutral trend. The MACD of 0.04 indicates Positive momentum. The RSI at 53.67 is Neutral, neither overbought nor oversold. The STOCH value of 18.20 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AWHL.

Aspira Women's Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SERA	49 Neutral	122.18M	-3.77	-68.82%	―	0.93%	13.99%
AWHL	48 Neutral	$14.80M	―		―	4.10%	67.32%
VNRX	43 Neutral	67.13M	-2.56	73.31%	―	35.10%	39.15%
BDSX	42 Neutral	49.68M	-1.20	-3609.67%	―	25.70%	39.25%
INBS	41 Neutral	12.73M	-0.69	-352.75%	―	-1.90%	87.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Aspira Women's Health Corporate Events

Aspira Women’s Health Appoints New CFO Brian Hungerford

On September 2, 2025, Aspira Women’s Health appointed Brian Hungerford as its Chief Financial Officer and Principal Accounting Officer, replacing Julie Carrillo. Hungerford, with over 20 years of experience, previously served as CFO for Kiromic Biopharma, Inc. His compensation package includes a $300,000 annual salary, a potential 35% cash bonus, and stock options. The Consulting Agreement outlines terms for salary continuation and stock option vesting in the event of termination without cause or following a change of control.

Aspira Women’s Health Appoints Jane Pine Wood to Board

On July 11, 2025, Aspira Women’s Health appointed Jane Pine Wood to its Board of Directors. Ms. Wood brings over 38 years of legal experience in healthcare, having worked with a diverse range of healthcare providers. Her expertise is expected to support Aspira’s growth and drive advancements in women’s healthcare. This strategic appointment is likely to enhance the company’s operations and strengthen its position in the women’s health diagnostics industry.

Aspira Women’s Health Ends ARPA-H Contract

On June 11, 2025, Aspira Women’s Health announced the termination of its contract with the Advanced Research Projects Agency for Health (ARPA-H) for the Sprint for Women’s Health initiative. Despite receiving $3.5 million of the $10 million award, ARPA-H determined that Aspira did not meet the specifications of Milestone 3, leading to the contract’s termination. Aspira’s CEO expressed confidence in the company’s progress and commitment to continue developing the ENDOinform test, which aims to improve the diagnosis and treatment of endometriosis, with a target completion in 2026.